VR Logo

Unrated

Tata India Pharma & HealthCare Fund - Regular Plan


1 Lakh

Investment Grown to
₹ 1.63 Lakh

₹ 10000

Monthly SIP Grown to
₹ 5.42 Lakh

Suitability:

This is a fund that invests mainly in shares of pharmaceutical and healthcare companies.

We believe that investors should avoid funds that have a narrowly defined investment mandate such as this one. Instead, they should invest in multi-cap funds which provide complete freedom to the fund management team to invest in companies from which it expects maximum gains.

But if you do invest, you must do so only through the SIP route. Click here to read a primer on SIP investing.

Warning: Do not invest in this, or any other pharma sector fund, if you need to redeem your investment in less than seven years.

Taxability of earnings:

Capital gains

  • If the mutual fund units are sold after 1 year from the date of investment, gains upto Rs 1 lakh in a financial year are exempt from tax. Gains over Rs 1 lakh are taxed at the rate of 10%.
  • If the mutual fund units are sold within 1 year from the date of investment, entire amount of gain is taxed at the rate of 15%.
  • No tax is to be paid as long as you continue to hold the units.

Dividends

  • Dividends are added to the income of the investors and taxed according to their respective tax slabs. Further, if an investor's dividend income exceeds Rs. 5,000 in a financial year, the fund house also deducts a TDS of 10% before distributing the dividend.

Read more

ajax-loader
Please wait...

ajax-loader
Please wait...

(₹)
cal
cal

ajax-loader
Please wait...

Trailing Returns (%)

YTD 1-Day 1-W 1-M 3-M 6-M 1-Y 3-Y 5-Y 7-Y 10-Y
Fund 53.35 1.12 3.39 5.36 12.29 26.97 51.16 17.67 -- -- --
S&P BSE Healthcare TRI 52.39 0.97 3.03 5.57 10.58 30.29 50.44 14.05 -- -- --
Equity: Sectoral-Pharma 56.11 0.99 2.98 5.22 10.97 29.45 55.77 16.75 -- -- --
Rank within category 7 3 2 4 1 7 7 2 -- -- --
Number of funds in category 9 9 9 9 9 9 9 4 3 3 3

As on 27-Nov-2020

Peer Comparison

Fund name Rating Launch Date 1-Year Return 3-Year Return 5-Year Return Expense Ratio Assets (Cr)
Tata India Pharma & HealthCare Fund - Regular Plan  | Invest Online
Unrated
Dec-15 51.16 17.67 -- 2.64 354
Nippon India Pharma Fund
Unrated
Jun-04 56.62 20.34 10.24 2.03 3,900
ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund  | Invest Now
Unrated
Jul-18 58.19 -- -- 2.38 1,962
SBI Healthcare Opportunities Fund  | Invest Online
Unrated
Jul-99 54.82 13.31 4.85 2.42 1,445
Mirae Asset Healthcare Fund - Regular Plan  | Invest Online
Unrated
Jul-18 62.08 -- -- 2.36 1,036

Best & Worst Performance

Best (Period) Worst (Period)
Week 20.39 (01-Apr-2020 - 09-Apr-2020) -11.13 (05-Mar-2020 - 12-Mar-2020)
Month 31.54 (27-Mar-2020 - 27-Apr-2020) -18.44 (20-Feb-2020 - 23-Mar-2020)
Quarter 37.97 (23-Mar-2020 - 22-Jun-2020) -14.66 (26-Sep-2016 - 26-Dec-2016)
Year 63.02 (09-Oct-2019 - 08-Oct-2020) -18.70 (08-Sep-2016 - 08-Sep-2017)

Risk Measures (%)

Mean Std Dev Sharpe Sortino Beta Alpha
Fund 16.48 19.77 0.58 1.17 0.81 4.83
S&P BSE Healthcare TRI 13.24 23.70 0.35 0.86 -- --
Equity: Sectoral-Pharma 15.99 20.97 0.53 1.12 0.86 3.90
Rank within category 2 1 2 2 1 2
Number of funds in category 4 4 4 4 4 4

The Risk Measures have been calculated using calendar month returns for the last three years.

As on 31-Oct-2020

Asset Allocation (%)

ajax-loader
Please wait...

Concentration & Valuation

Number of Stocks 22
Top 10 Stocks (%) 72.17
Top 5 Stocks (%) 48.08
Top 3 Sectors (%) 95.51
Portfolio P/B Ratio 4.73
Portfolio P/E Ratio 43.23

Portfolio Aggregates

Fund Category
Average Mkt Cap (Rs Cr) 32,139 33,277
Giant (%) 9.51 8.95
Large (%) 40.93 46.55
Mid (%) 36.39 31.97
Small (%) 13.17 12.53
Tiny (%) -- --

Value Research Fund Style

Sector Allocation vis-à-vis Category

ajax-loader
Please wait...

Top Holdings

Company Sector P/E 3Y High 3Y Low % Assets
equal Dr. Reddy's Lab Healthcare 49.91 17.99 0.00 13.85
equal Sun Pharmaceutical Inds. Healthcare 83.46 23.13 5.93 9.08
equal Cipla Healthcare 32.63 9.44 0.00 8.74
equal Divi's Laboratories Healthcare 54.45 10.88 4.69 8.21
up Ipca Laboratories Healthcare 27.96 11.01 5.90 8.20
equal Narayana Hrudayalaya Healthcare -- 6.67 0.00 6.05
equal Lupin Healthcare -- 10.47 1.38 5.21
equal Laurus Labs Healthcare 28.44 5.05 0.00 5.05
up Syngene International Healthcare 65.28 7.99 0.00 4.00
equal Procter & Gamble Health Healthcare 59.23 7.30 0.00 3.78
up Alkem Laboratories Healthcare 23.19 6.44 0.00 3.65
equal Indoco Remedies Healthcare 42.13 3.39 0.00 3.23
equal Apollo Hospitals Healthcare 198.91 6.51 1.80 3.14
equal Natco Pharma Healthcare 32.05 3.59 0.00 2.24
equal Aurobindo Pharma Healthcare 16.19 7.22 0.00 2.18
equal JB Chemicals & Pharma Healthcare 24.81 1.97 0.00 1.91
equal Dr. Lal Pathlabs Healthcare 95.33 1.88 0.00 1.88
equal Healthcare Global Enterprises Healthcare -- 4.16 0.00 1.39
equal Abbott India Healthcare 49.67 11.41 1.23 1.23
new Fortis Healthcare (India) Healthcare -- 0.98 0.00 0.98
equal Cadila Healthcare Healthcare 27.21 5.48 0.89 0.90
equal Astrazeneca Pharma India Healthcare 139.64 0.80 0.00 0.61

up down equal Indicates an increase or decrease or no change in holding since last portfolio
new Indicates a new holding since last portfolio

As on 31-Oct-2020

Fund Manager

— Meeta Shetty since 09-Nov-2018

Education: Ms. Shetty is Bachelor in Economics and CFA Charterholder

Experience: Prior to joining TATA Mutual Fund, she has worked with Kotak Securities, HDFC Securities, AMSEC(Asian Market Securities), Dalal & Broacha Stock Broking and karvey Stock Broking.

Funds Managed:

— Rahul Singh since 20-Apr-2020

Education: Mr. Singh is B.Tech & PGDBM

Experience: Prior to Tata AMC, he has worked with Ampersand Capital Investment Advisors LLP, Standard Chartered Securities and Citigroup Global Markets India.

Funds Managed:


1.12%

Change from previous, NAV as on 27-Nov-2020

Growth: ₹ 14.1168

Dividend: ₹ 14.1168


Investment Strategy

The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.

Investment Details

Minimum Investment (₹) 5,000
Minimum Addl Investment (₹) 1,000
Minimum SIP Investment (₹) 150
Minimum No of Cheques 12
Minimum Withdrawal (₹) 500
Minimum Balance (₹) 500
Exit Load For units in excess of 12% of the investment,1% will be charged for redemption within 365 days

Basic Details

Fund House: Tata Mutual Fund
Launch Date: 28-Dec-2015
Return Since Launch: 7.26%
Benchmark: NIFTY Pharma TRI
Riskometer: High
Type: Open-ended
Assets: ₹ 354 Cr (As on 31-Oct-2020)
Expense: 2.64% (As on 31-Oct-2020)
Risk Grade: --
Return Grade: --
Turnover: 58.89%

Contact Information

AMC: Tata Asset Management Private Ltd

Address: 9th Floor, Mafatlal Centre, Nariman Point, Mumbai - 400021

Phone: 1800-209-0101

Email: [email protected]

Website: http://www.tatamutualfund.com

Registrar & Transfer Agent: Computer Age Management Services Ltd.

Address: 7th Floor, Tower II, Rayala Towers, 158, Anna Salai, Chennai - 600002

Phone: 1800-3010-6767 / 1800-419-7676

Fax: 044-30407101

Email: [email protected]

Website: www.camsonline.com

Last Session

VR Helpline

Critical Investment Decisions

dateSaturday, 28-Nov-2020
time04:00 PM - 04:30 PM

Registration Over